[The effect of dipyridamole on coagulation status in stenocardia].
P Ficović, Z Gjurić, Z Grgić
Abstract
P Ficović, Z Gjurić, Z Grgić
Abstract
The laboratory examination of Dipyridamole concerning its antiaggregation effect is presented in the paper. Thirty patients with coronary insufficiency have been taking Dipyridamole for one year. The average dosage was four pills à 75 mg of Dipyridamole a day. The aggregation and adhesion of the platelets with the examined patients was checked before and during the treatment. The inhibition platelet aggregation with Dipyridamole has been confirmed in vitro.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The laboratory examination of Dipyridamole concerning its antiaggregation effect is presented in the paper. Thirty patients with coronary insufficiency have been taking Dipyridamole for one year. The average dosage was four pills à 75 mg of Dipyridamole a day. The aggregation and adhesion of the platelets with the examined patients was checked before and during the treatment. The inhibition platelet aggregation with Dipyridamole has been confirmed in vitro.
Key concepts: Dipyridamole, Medicine, Platelet aggregation, Coagulation, Platelet, Cardiology, Internal medicine, Pill